Skip to main content

Table 5 Arsenic concentrations in PB and BM plasma collected during the remission induction therapy

From: Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient

Days after the start of administration -1 14 28 42 56
Clinical samples PB BM PB BM PB BM PB BM PB BM
Arseni concentrations (ngAs/g) As(V) 0.36 0.35 1.26 0.54 1.50 1.91 0.99 2.34 0.24 0.17
  As(III) 0 0 6.31 3.43 7.89 7.47 5.83 4.00 0.09 0.10
  MA(V) 0.55 0.80 10.6 12.4 13.5 12.4 14.0 13.0 1.87 1.63
  DMA(V) 0.11 0.63 13.2 11.5 13.3 12.1 15.3 15.1 3.96 3.21
  AB 0.60 0.51 0.43 3.49 3.80 0.50 0.99 0.99 1.22 1.00
  1. Blood samples and BM aspirations were collected before the treatment start (day -1), and 14, 28, 42, and 56 days after the start of administration. The concentrations of arsenic species in PB and BM plasma were determined by HPLC/ICP-MS as described in "Patient and Methods".